Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Astex Therapeutics Ltd. maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area, currently featuring 1 pending office action. This 1 pending office action suggests a targeted approach to its pharmaceutical intellectual property, focusing on a specific therapeutic candidate. The presence of 1 pending office action indicates a period of focused negotiation with the USPTO regarding its biotechnology claims.
The prosecution landscape for this company is narrow, involving 1 distinct examiner and 1 distinct art unit. This concentration means that the company's current patenting success depends on navigating the specific hurdles of a single technical area within the patent office. For the practitioner, the relationship between the portfolio and the 1 distinct art unit simplifies the monitoring of relevant prior art and examination trends.
The busiest examiner for this portfolio is HOWELL, THEODORE R, who is currently overseeing the 1 pending office action. As the sole examiner involved in the company's active cases, HOWELL, THEODORE R is the primary arbiter of the company's patent claims. The 1 pending office action under HOWELL, THEODORE R represents the entirety of the company's current prosecution challenges in the biotechnology sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOWELL, THEODORE R | 1 | 66.8% | +25.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18317762 | PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE | HOWELL, THEODORE R | 65d |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18317762 | PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE | HOWELL, THEODORE R | 1628 | §112Other | Final Rejection | 65d | Pending | May 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial